Article info
PDFOvarian Cancer
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
- Address correspondence and reprint requests to Amit M. Oza, MD, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto M5G 2M9, Canada. E-mail: amit.oza{at}uhn.on.ca.
Citation
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
Publication history
- Received June 30, 2016
- Accepted August 2, 2016
- First published January 1, 2016.
Online issue publication
March 01, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.